Monitoring therapeutic efficacy of sunitinib using [18F]FDG and [18F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-015-1540-2
Published Online: 2015-07-22
Published Print: 2015-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Thézé, Benoît
Bernards, Nicholas
Beynel, Audrey
Bouet, Stephan
Kuhnast, Bertrand
Buvat, Irène
Tavitian, Bertrand
Boisgard, Raphaël
License valid from 2015-07-22